RETA 20mg

Retatrutide is an investigational multi-agonist peptide designed to target GLP-1, GIP, and glucagon receptors simultaneously. By activating these pathways, it has been shown in research settings to:

• Support glucose regulation and improve insulin sensitivity

• Promote weight reduction through appetite control and increased energy expenditure

• Enhance metabolic function via triple hormone signaling

• Offer potential benefits in cardiometabolic health and obesity management

Retatrutide is currently under investigation in clinical trials for its ability to deliver greater efficacy than single-pathway agonists such as GLP-1 analogues alone. Its unique triple-agonist mechanism makes it one of the most promising new compounds in metabolic and weight-related research.

Disclaimer

• For Research Purposes Only – Retatrutide is not approved by Health Canada, the FDA, or any regulatory body for human consumption.

• This product is not intended for human or veterinary use and must not be misused as a drug, food additive, or supplement.

• Information provided is for educational and laboratory research purposes only.

• Buyers assume full responsibility for proper handling, storage, and lawful use.

• By purchasing, you confirm that you are a qualified researcher or institution.